Abstract
Oral indomethacin administration (2 mg/kg/d) was investigated in rats with adjuvant arthritis up to a period of 5 wk. Baseline low serum zinc levels in arthritic rats increased rapidly from the first week of indomethacin treatment (started 1 or 2 wk after disease induction), whereas baseline high serum copper decreased after 1–2 wk. After 3–4 wk of treatment, serum zinc levels returned to control values, but serum copper was somewhat higher in arthritic animals having received indomethacin 2 wk after disease induction than in controls. Clinical indices of inflammation simultaneously improved to reach control values at the end of the trial. Biological indicators of inflammation also improved, but did not reach control levels. Serum zinc correlated negatively with plasma fibrinogen (r=−0.69,p<0.005) and serum copper correlated positively with serum ceruloplasmin (r=0.92,p<0.0005) both in indomethacin-treated and untreated arthritic rats. Contrary to long-term glucocorticoid administration that was previously reported to maintain or aggravate hypozincemia, indomethacin treatment normalized perturbed zinc and copper status in arthritic animals.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
R. J. Cousins,Physiol. Rev. 65, 238–309 (1985).
A. L. Conforti, L. Franco, R. Milanino, and G. P. Velo,Agents and Actions 12, 2, 303–307 (1982).
K. C. Klasing,Am. J. Physiol. 247, 2901–2904 (1984).
A. Peretz, J. Nève, and J. P. Famaey,J. Trace Element Electrolytes Health Dis. 3, 103–108 (1989).
A. A. R. Youssef, B. Wood, and D. N. Baron,J. Clin. Pathol. 36, 14–17 (1983).
H. Mussalo-Rauhamaa, Y. T. Konttinen, J. Letho, and V. Honkanen,Ann. Rheum. Dis. 47, 816–819 (1988).
V. Kishore, N. Latman, D. W. Roberts, J. B. Barnett, and J. R. J. Sorenson,Agents and Actions 42, 2, 274–282 (1984).
R. A. Disilvestro,Nutr. Res. 10, 355–360 (1990).
M. T. Ercan and N. M. Bor,Nucl. Med. Biol. 18, 7, 765–773 (1991).
M. W. Whitehouse, K. D. Rainsford, R. M. Taylor, and B. Vernon-Roberts,Agents and Actions 31, 1/2, 47–58 (1990).
J. R. Sorenson,Prog. Med. Chem. 15, 211–260 (1978).
J. Fontaine, J. Nève, A. Peretz, P. Capel, and J. P. Famaey,Agents and Actions 33, 3/4, 247–253 (1991).
C. D. Klaassen,Toxicology 20, 275–280 (1981).
J. Fontaine, J. Nève, A. Peretz, and J. P. Famaey,Biol. Trace Elem. Res. 32, 355–362 (1992).
M. Chapvil, L. Stanicova, and P. Weldy, inZinc Metabolism, Currents Aspects in Health and Disease, A Prasad, ed., p. 103–122 (1976).
J. Fontaine, J. Nève, A. Peretz, F. Pelen, and J. P. Famaey,Int. J. Tissue React. 11, 253–259 (1989).
A. Von Clauss,Acta Hematol. 17, 237–246 (1957).
F. W. Sunderman Jr. and S. Nomoto,Clin. Chem. 16, 903–908 (1970).
P. Scudder, J. Stocks, and T. L. Dormandy,Clin. Chim. Acta 69, 397–403 (1976).
J. Dawson and B. Walker,Clin. Chim. Acta 26, 465–475 (1969).
J. Nève, A. Fontaine, A. Peretz, and J. P. Famaey,Agents and Actions 25, 146–155 (1988).
V. Kishore,Res. Commun. Chem. Pathol. Pharmacol. 63, 153–156 (1989).
I. M. Goldstein, H. B. Kaplan, H. S. Edelson, and G. Weissman,J. Biol. Chem. 254, 4040–4048 (1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Quivy, D., Nève, J., Fontaine, J. et al. Trace element status and inflammation parameters during chronic indomethacin treatment in adjuvant arthritic rats. Biol Trace Elem Res 47, 209–218 (1995). https://doi.org/10.1007/BF02790119
Issue Date:
DOI: https://doi.org/10.1007/BF02790119